{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"9"}]}],"title":"4M PFS by Independent Image Review"},{"categories":[{"measurements":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"13"}]}],"title":"4M PFS by Site assess"}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"23"}],"units":"Participants"}],"description":"Planned: Forty-two patients were to be treated in Arm A. If ≥ 23 patients (\\>54%) were free of progression and death at 4 months, then the study regimen would be considered for further evaluation in this indication.","groups":[{"description":"Pemetrexed, Cisplatin, and CBP501 administered once every 3 weeks","id":"OG000","title":"Pemetrexed, Cisplatin, and CBP501"},{"description":"Pemetrexed and Cisplatin every three weeks","id":"OG001","title":"Pemetrexed and Cisplatin"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"End of study","title":"4M PFS Rate of Patients With Previously Untreated, Unresectable Malignant Pleural Mesothelioma (MPM) Treated With CBP501, Pemetrexed and Cisplatin","type":"PRIMARY","unitOfMeasure":"participants"}